Champions Oncology Valuation
| CSBR Stock | USD 4.56 0.02 0.44% |
At this time, the firm appears to be undervalued. Champions Oncology shows a prevailing Real Value of $5.51 per share. The current price of the firm is $4.56. Our model approximates the value of Champions Oncology from analyzing the firm fundamentals such as profit margin of (0.07) %, and Return On Equity of -4.32 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Champions Oncology's valuation include:
Price Book 6.7705 | Enterprise Value 65.9 M | Enterprise Value Ebitda 26.2588 | Price Sales 1.208 | Forward PE 22.8833 |
Undervalued
Today
Please note that Champions Oncology's price fluctuation is moderately volatile at this time. Calculation of the real value of Champions Oncology is based on 3 months time horizon. Increasing Champions Oncology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Champions stock is determined by what a typical buyer is willing to pay for full or partial control of Champions Oncology. Since Champions Oncology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Champions Stock. However, Champions Oncology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.56 | Real 5.51 | Target 8.75 | Hype 4.54 | Naive 4.41 |
The intrinsic value of Champions Oncology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Champions Oncology's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Champions Oncology helps investors to forecast how Champions stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Champions Oncology more accurately as focusing exclusively on Champions Oncology's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Champions Oncology's intrinsic value based on its ongoing forecasts of Champions Oncology's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Champions Oncology's closest peers.
Champions Oncology Cash |
|
Champions Valuation Trend
Champions Oncology's real value is important for investors to make better decisions and a more accurate overall view of Champions Oncology's financial worth over time. Using both Champions Oncology's enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Champions Revenue by Product
Champions Oncology Total Value Analysis
Champions Oncology is currently forecasted to have valuation of 65.93 M with market capitalization of 62.4 M, debt of 7.43 M, and cash on hands of 8.06 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Champions Oncology fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
65.93 M | 62.4 M | 7.43 M | 8.06 M |
Champions Oncology Investor Information
About 26.0% of the company shares are held by company insiders. The company has Price/Earnings (P/E) ratio of 220.0. Champions Oncology recorded a loss per share of 0.26. The entity had not issued any dividends in recent years. The firm had 1:12 split on the 12th of August 2015. Based on the key measurements obtained from Champions Oncology's financial statements, Champions Oncology may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter.Champions Oncology Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Champions Oncology has an asset utilization ratio of 191.93 percent. This connotes that the Company is making $1.92 for each dollar of assets. An increasing asset utilization means that Champions Oncology is more efficient with each dollar of assets it utilizes for everyday operations.Champions Oncology Ownership Allocation
The market capitalization of Champions Oncology is $62.4 Million. Over half of Champions Oncology's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Champions Oncology Profitability Analysis
The company reported the previous year's revenue of 50.16 M. Net Loss for the year was (7.28 M) with profit before overhead, payroll, taxes, and interest of 24.34 M.About Champions Oncology Valuation
The stock valuation mechanism determines Champions Oncology's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Champions Oncology based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Champions Oncology. We calculate exposure to Champions Oncology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Champions Oncology's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 20.8 M | 21.8 M | |
| Pretax Profit Margin | (0.15) | (0.15) | |
| Operating Profit Margin | (0.14) | (0.14) | |
| Net Loss | (0.15) | (0.15) | |
| Gross Profit Margin | 0.41 | 0.53 |
Champions Oncology Growth Indicators
Investing in growth stocks can be very risky. If the company such as Champions Oncology does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 13.5 M | |
| Quarterly Earnings Growth Y O Y | -0.286 | |
| Forward Price Earnings | 22.8833 |
Champions Oncology Current Valuation Indicators
Champions Oncology's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Champions Oncology's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Champions Oncology, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Champions Oncology's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Champions Oncology's worth.Additional Tools for Champions Stock Analysis
When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.